HDFC Mid Cap Fund
The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies.
Growthvine rating: 5/5 — ranked #1 of 34 in category.
Fund basics
| Category | Equity: Mid Cap |
|---|
| NAV | ₹197.82 (as of 2026-10-01) |
|---|
| AUM | ₹1,08,325 Cr |
|---|
| Expense ratio | 1.08% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Chirag Setalvad |
|---|
| Exit load | 1% for redemption within 365 days |
|---|
Performance & risk
| 5-year annualised return | 16.74% |
|---|
| Sharpe ratio | 0.81 |
|---|
| Standard deviation | 15.33% |
|---|
| Max drawdown | −60.80% |
|---|
| Alpha | 2.49 |
|---|
| Beta | 0.84 |
|---|
Over 5 years, captured 93.6% of NIFTY Midcap 150's upside and 78.3% of its downside.
Market cap allocation
| Large cap | 11.3% |
|---|
| Mid cap | 70.4% |
|---|
| Small cap | 18.3% |
|---|
Concentration
| Top 5 holdings | 18.3% |
|---|
| Top 10 holdings | 32.3% |
|---|
| Total holdings | 79 |
|---|
| Index overlap | 29.4% |
|---|
| Active share | 70.6% |
|---|
Top holdings
- TREPS - Tri-party Repo — 6.9%
- Federal Bank Ltd. — 4.2%
- AU Small Finance Bank Limited — 4.0%
- Max Financial Services Limited — 3.8%
- Ipca Laboratories Ltd. — 3.3%
- Glenmark Pharmaceuticals ltd — 3.1%
- Indian Bank — 3.1%
- Balkrishna Industries Ltd. — 3.0%
- COFORGE LIMITED — 2.9%
- Fortis Healthcare Ltd — 2.7%
Top sectors
- Banking & Financial — 17.2%
- Pharma & Biotech — 11.7%
- Automobile — 9.6%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −2.8% | Q4 (Bottom) | #29 of 31 |
| 2025 | 6.8% | Q1 (Top) | #3 of 29 |
| 2024 | 28.6% | Q2 | #15 of 29 |
| 2023 | 44.5% | Q1 (Top) | #4 of 28 |
| 2022 | 12.3% | Q1 (Top) | #2 of 22 |